COVID-19 Monoclonal Antibody Provider Guidance: Bebtelovimab

Eligibility

- Mild-moderate COVID-19 within 7 days of symptom onset
- Risk of progression to severe COVID-19, a list of qualifying conditions can be found in Appendix F of SARS CoV-2 guidance
- Age ≥12 years old and weight ≥ 40 kg
- Meet UIHC COVID Risk Stratification Score eligibility criteria (subject to change based on available drug supply)

Dosing

- 175 mg administered as a single IV injection over at least 30 seconds
- No renal or hepatic dose adjustments are recommended

Contraindications of authorized use in patients

- Hospitalized due to COVID-19
- Require oxygen therapy and/or respiratory support due to COVID-19
- Require an increase in baseline oxygen flow rate and/or respiratory support due to COVID-19 and are on chronic oxygen therapy and/or respiratory support due to underlying non-COVID-19 conditions

Lab monitoring

- None

Drug interactions

- None

Hypersensivity including anaphylaxis and infusion-related reactions

- Serious hypersensitivity reactions, including anaphylaxis, have been observed with other COVID-19 monoclonal antibody drug products and could occur with the administration of bebtelovimab
- Patients are monitored for 60 minutes following administration of bebtelovimab

Common adverse reactions

- Infusion-related reactions (0.3%), pruritus (0.3%), rash (0.8%)

COVID-19 variant susceptibility

- COVID-19 monoclonal antibody drug product administered to patients will be updated as necessary based on geographic variant circulation and susceptibility monitoring

More information

- University of Iowa Health Care Guidance on Treatment Options for Patients with SARS-CoV-2 Appendix F

Updated 6/23/2022